Publications » 2002 » Other publications » Print version (formatted)

Other publications
11Moberg C.; Belda O.; Hallman K.; Stranne R.; Svensson M.; Vasse J.-L.; Wondimagegn T.; Zalubovskis R. Chiral metal complexes in asymmetric catalysis. In Perspectives in Organometallic Chemistry. Ed. by C.G.Screttas and B.R.Stille. 2002, 275.      

12Сьяксте Н.И.; Сьяксте Т.Г. Структура геномных доменов генов глобинов млекопитающихся и птиц:[обзор] . Genetika. 2002, 38(12), 1342-1358.      

13Страдынь Я.; Гасанов Б. Анодная вольтамперометрия производных фенола и тиофенола. 4. Эффекты заместителей на потенциалы электроокисления мета- и пара-монозамещенных фенолов. Latvian J. Chem. 2002(2), 169-185.      

14Соколов Г.П.; Туровскис И.В.; Лукевиц Э. Синтез фосфатов длинноцепочечных омега-гидроксиалкиловых эфиров 11-дезоксипростагландина Е1. Bioorg. Chem. Bioorg. Khim. 2002, 28(1), 69-71.      

15Калвиньш И. Милдронат и триметазин: сходство и различие. Terra Medica. 2002(3), 3-5.      

16Кажока Х.; Муцениеце Д. Анализ фенилина в условиях нормально-фазовой высокоэффективной жидкостной хроматографии. Latvian J. Chem. 2002(2), 193-198.      

17Veveris M.; Gorshkova O.; Kleina R.; Meirena D.; Kalvins I. Effect of Mildronate on experimental atherosclerosis with and without endothelial dysfunction. Balt. J. Lab. Anim. Sci. 2002, 12(1-2), 116-122.      

18Sokolov G.P.; Turovskii I.V.; Lukevics E. The synthesis of phosphates of long-chain g-hydroxylalkyl esters of 11-deoxyprostaglandin E1. Russ. J. Bioorgan. Chem. 2002, 28(1), 62-64.      

19Sjakste N.; Sjakste T.; Rumba I.; Vikmanis U. Proteasomes in patology:[review] . Proc.Latvian Acad.Sci., Sect.B. 2002, 56(1/2), 7-16.      

20Lukevics E.; Pudova O. Chapter 24: Biological activity of organotin and organolead compounds: [In The chemistry of organic germanium, tin and lead compounds. Ed. Z. Rappoport. Chichester, England]. John Wiley & Sons, Ltd. 2002, 2(2), 1685-1714.      

21Lukevics E.; Pudova O. Silyl imidic esters. Science of synthesis. Houben-Weyl Methods of molecular transformations. Organometallics. Stuttgart; New York: Georg Thieme Verlag. 2002, 4: Compounds of group 15 (As, Sb, Bi), 305-315.      

22Lukevics E.; Ignatovich L. Chapter 23: Biological activity of organogermanium compounds: [The chemistry of organic germanium, tin and lead compounds. Ed. Z. Rappoport. Chichester, England] . John Wiley & Sons, Ltd. 2002, 2(2), 1653-1683.      

23Kooijman H.; Spek A.L.; Sobolev A.; Jongejan H.; Franssen M.C.R. 3-Methyl 5-[(S)-2-methylbutyl] 4-[2-(difluoromethoxy)phenyl]-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate . Acta Crystallogr., Sect.E. 2002, E58(5), 532-534.      

24Kalvinsh I. Myocardial metabolism and ischemia. Educational Progress on Acute and Chronic Myocardial Ischemia, 19-21 September, Moscow, Russia. 2002, 1-17.      

25Freimanis J.; Stonkus V. Lietoto ziežeļļu pārstrādāšana Latvijā . Latvijas ķīmijas žurnāls 2002(3), 303-316.      

26Fleisher M.; Stonkus V.; Leite L.; Lukevics E. Theoretical investigations of 1,4-butanediol and 2-butene-1,4-diol cyclodehydration using postprocessing visualization of quantum chemical calculation data. International J. of Quantum Chem. 2002, 88, 670-675.      

27Briede J.; Heidemanis K.; Dabiņa I.; Duburs G. Effect of cerebrocrast on the function of human platelets and release of the arachidonic acid from plasma membrane . Cell. Biochem. Funct. 2002, 20, 177-181.      

28Andersons A.; Simonyan S.; Lukevics E. Pyrrole-pyridine interconversions on the tungsten catalyst . Latvian J. Chem. 2002(2), 199-204.      

29Slavinska V.; Sīle Dz.; Rozentāls G.; Balodis J.; Čipēns G.; Lidaka M.; Lukevics E. Rūpnieciskā 1,6% Pd/C katalizatora aktivitāte un selektivitāte N-benziloksikarbonilprolilarginīna hidrogenolīzē un citās peptīdu starpproduktu sintēzes reakcijās. 1: Materiālzinātne un lietišķa ķīmija. Vol.5. RTU zin. raksti. 2002, 126-133.      

30Polevaya L.; Roumelioti P.; Mavromoustakos T.; Zoumpoulakis P.; Giatas N.; Mutule I.; Keivish T.; Zoga A.; Vlahakos D.; Iliodromitis E.; Kremastinos D.; Matsoukas J. Design, synthesis and biological evaluation of cyclic Angiotensin II analogues with 3,5 side-chain bridges: Role of C-terminal aromatic residue and positions 3,5 for activity. (Drug discovery and design: Medical aspects, eds.J.Matsuokas, T.Mavromoustakos. Netherlands, IOS Press) . Biomed. Heals Res. 2002, 55, 3-12.      

31Sīle Dz.; Slavinska V.; Venteris K.; Čipēns G.; Balodis J.; Rozentāls G.; Lukevics E. 2-Okso-4-fenilbutēnskābes etilestera vienstadijas sintēze. 1: Materiālzinātne un lietišķa ķīmija. Vol.5. RTU zin. raksti. 2002, 42-46.      

32Mishnev A. A new approach to the phase problem solution based on the half-integral structure factors. Latv.J.Phys.Techn.Sci. 2002(5), 50-56.      

33Andersons A.; Simonyan S.; Lukevics E. Influence of the catalyst support nature on interconversions of five- and six-membered nitrogen-containong heterocycles . Latvian J. Chem. 2002(4), 429-433.      

34Ābele E.; Dzenitis O.; Lukevics E. Novel fluoride ion-mediated O-silylation method of aromatic and heterocyclic oximes with azidotrimethylsilane under phase transfer catalysis conditions. Latvian J. Chem. 2002(4), 418-420.